CA3078675A1 - Genetic regulation - Google Patents
Genetic regulation Download PDFInfo
- Publication number
- CA3078675A1 CA3078675A1 CA3078675A CA3078675A CA3078675A1 CA 3078675 A1 CA3078675 A1 CA 3078675A1 CA 3078675 A CA3078675 A CA 3078675A CA 3078675 A CA3078675 A CA 3078675A CA 3078675 A1 CA3078675 A1 CA 3078675A1
- Authority
- CA
- Canada
- Prior art keywords
- chromosome
- responder
- interactions
- nucleic acids
- probe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762581287P | 2017-11-03 | 2017-11-03 | |
| US62/581,287 | 2017-11-03 | ||
| GBPCT/GB2018/052818 | 2018-10-03 | ||
| GB2018052818 | 2018-10-03 | ||
| PCT/GB2018/053196 WO2019086898A2 (en) | 2017-11-03 | 2018-11-02 | Genetic regulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3078675A1 true CA3078675A1 (en) | 2019-05-09 |
Family
ID=64661410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3078675A Pending CA3078675A1 (en) | 2017-11-03 | 2018-11-02 | Genetic regulation |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11840737B2 (enExample) |
| EP (1) | EP3704274B1 (enExample) |
| JP (2) | JP2021501592A (enExample) |
| KR (1) | KR102885025B1 (enExample) |
| CN (1) | CN111511930B (enExample) |
| AU (1) | AU2018361833B2 (enExample) |
| CA (1) | CA3078675A1 (enExample) |
| ES (1) | ES2987603T3 (enExample) |
| HU (1) | HUE066292T2 (enExample) |
| MY (1) | MY199800A (enExample) |
| PL (1) | PL3704274T3 (enExample) |
| SG (1) | SG11202003233YA (enExample) |
| WO (1) | WO2019086898A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3152645A1 (en) * | 2019-09-11 | 2021-03-18 | Oxford BioDynamics PLC | Diagnostic chromosome marker |
| EP4121964A1 (en) * | 2020-03-17 | 2023-01-25 | Regeneron Pharmaceuticals, Inc. | Methods and systems for determining responders to treatment |
| GB202008269D0 (en) * | 2020-06-02 | 2020-07-15 | Oxford Biodynamics Ltd | Detecting a chromosome marker |
| GB202016176D0 (en) * | 2020-10-12 | 2020-11-25 | Oxford BioDynamics PLC | Disease marker |
| TW202302862A (zh) * | 2021-03-04 | 2023-01-16 | 英商牛津生物力學公眾有限公司 | 染色體交互作用標記物 |
| WO2025215189A1 (en) * | 2024-04-12 | 2025-10-16 | Oxford BioDynamics PLC | Chromosome marker test |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR036993A1 (es) * | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| GB0603251D0 (en) | 2006-02-17 | 2006-03-29 | Isis Innovation | DNA conformation |
| AU2008204338B2 (en) | 2007-01-11 | 2014-03-06 | Erasmus University Medical Center | Circular chromosome conformation capture (4C) |
| WO2009051268A2 (en) | 2007-10-15 | 2009-04-23 | Takeda Pharmaceutical Company Limited | Preventive/remedy for cancer |
| GB0810051D0 (en) | 2008-06-02 | 2008-07-09 | Oxford Biodynamics Ltd | Method of diagnosis |
| BRPI1007093A2 (pt) | 2009-05-12 | 2017-06-06 | Koninl Philips Electronics Nv | fosfodiesterase 4d7 uso de pde4d7; composição metodo, metodo de aquisição de dados imunoensaio para detectar diagnosticar, monitorar ou prognosticar cancer de prostata ou para diagnosticar, detectar monitorar ou prognosticar progressao do cancer |
| EP3004877A4 (en) * | 2013-06-06 | 2017-04-19 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms |
| WO2015077414A1 (en) | 2013-11-20 | 2015-05-28 | Dana-Farber Cancer Institute, Inc. | Kynurenine pathway biomarkers predictive of anti-immune checkpoint inhibitor response |
| JP2018518203A (ja) * | 2015-06-24 | 2018-07-12 | オックスフォード バイオダイナミックス リミテッド | エピジェネティックな染色体相互作用 |
-
2018
- 2018-11-02 HU HUE18815789A patent/HUE066292T2/hu unknown
- 2018-11-02 WO PCT/GB2018/053196 patent/WO2019086898A2/en not_active Ceased
- 2018-11-02 AU AU2018361833A patent/AU2018361833B2/en active Active
- 2018-11-02 US US16/760,541 patent/US11840737B2/en active Active
- 2018-11-02 CA CA3078675A patent/CA3078675A1/en active Pending
- 2018-11-02 KR KR1020207012736A patent/KR102885025B1/ko active Active
- 2018-11-02 ES ES18815789T patent/ES2987603T3/es active Active
- 2018-11-02 CN CN201880083380.6A patent/CN111511930B/zh active Active
- 2018-11-02 EP EP18815789.5A patent/EP3704274B1/en active Active
- 2018-11-02 MY MYPI2020002029A patent/MY199800A/en unknown
- 2018-11-02 JP JP2020524490A patent/JP2021501592A/ja active Pending
- 2018-11-02 PL PL18815789.5T patent/PL3704274T3/pl unknown
- 2018-11-02 SG SG11202003233YA patent/SG11202003233YA/en unknown
-
2023
- 2023-04-03 JP JP2023060384A patent/JP7631400B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018361833A1 (en) | 2020-04-30 |
| AU2018361833B2 (en) | 2021-04-22 |
| EP3704274A2 (en) | 2020-09-09 |
| ES2987603T3 (es) | 2024-11-15 |
| SG11202003233YA (en) | 2020-05-28 |
| MY199800A (en) | 2023-11-23 |
| HUE066292T2 (hu) | 2024-07-28 |
| US20210230702A1 (en) | 2021-07-29 |
| EP3704274C0 (en) | 2024-04-17 |
| US11840737B2 (en) | 2023-12-12 |
| KR20200081380A (ko) | 2020-07-07 |
| JP2023082157A (ja) | 2023-06-13 |
| PL3704274T3 (pl) | 2024-07-08 |
| NZ763540A (en) | 2025-03-28 |
| KR102885025B1 (ko) | 2025-11-11 |
| WO2019086898A3 (en) | 2019-06-13 |
| WO2019086898A2 (en) | 2019-05-09 |
| JP2021501592A (ja) | 2021-01-21 |
| CN111511930B (zh) | 2024-11-22 |
| JP7631400B2 (ja) | 2025-02-18 |
| CN111511930A (zh) | 2020-08-07 |
| EP3704274B1 (en) | 2024-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3078675A1 (en) | Genetic regulation | |
| US11913073B2 (en) | Methods for assessing risk of developing a viral disease using a genetic test | |
| US12412639B2 (en) | Method of characterizing a tumor based on an immune gene expression signature in regulatory T cell (Treg)-enriched tumor samples | |
| US12234513B2 (en) | Methods for assessing risk of developing a viral disease using a genetic test | |
| WO2016207661A1 (en) | Detection processes using sites of chromosome interaction | |
| Xia et al. | Single cell immunoprofile of synovial fluid in rheumatoid arthritis with TNF/JAK inhibitor treatment | |
| CN109988842B (zh) | 一种寡核苷酸标记探针原位检测pdl1的试剂组与应用 | |
| AU2020344206B2 (en) | Diagnostic chromosome marker | |
| WO2024025923A1 (en) | Methods for selection of cancer patients for anti-angiogenic and immune checkpoint blockade therapies and combinations thereof | |
| AU2021283746B2 (en) | Detecting a chromosome conformation as marker for fibrosis, e.g. scleroderma | |
| WO2025160307A1 (en) | Treating cancer using biomarkers and gene signatures | |
| Ammons | Use of Single-Cell RNA Sequencing and Comparative Immuno-Oncology to Gain Insights into Spontaneous Canine Cancers | |
| IL282089B2 (en) | A chromosome biomarker | |
| HK40110223A (en) | Methods for assessing risk of developing a viral disease using a genetic test | |
| HK40033107A (en) | Genetic regulation of immunoresponse by chromosome interactions | |
| HK40033107B (en) | Genetic regulation of immunoresponse by chromosome interactions | |
| Hoda | Gene expression signatures of human primary monocytes from healthy individuals and XLA patients using deep RNA sequencing analysis/Hoda Mirsafian |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231030 |